Menu +

Corcept Therapeutics to Announce Third Quarter 2016 Financial Results and Corporate Update and Host Conference Call

Download this Press Release     Download this Press Release

Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report third quarter financial results and provide a corporate update on November 1, 2016. The Company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).

Conference Call Information

To participate, dial 1-800-446-1671 from the United States or 1-847-413-3362 internationally approximately 10 minutes before the start of the call. The passcode is 43632675.

A replay will be available through November 15, 2016 at 1-888-843-7419 from the United States and 1-630-652-3042 internationally. The passcode is 43632675.

About Corcept Therapeutics Incorporated

Corcept is a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol. Korlym® (mifepristone) 300 mg tablets, a first-generation cortisol modulator, is the company‚Äôs first FDA-approved medication. The company also has a portfolio of proprietary compounds that modulate the effects of cortisol but not progesterone. Corcept owns extensive intellectual property covering the use of cortisol modulators, including mifepristone, in the treatment of a wide variety of serious disorders. It also holds composition of matter patents covering its selective cortisol modulators.


Charles Robb
Chief Financial Officer
Corcept Therapeutics

You are now leaving this website. If you would like to continue, click Continue.
Cancel Continue